BIOGAIA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 127.8 SEK | +2.90% |
|
+1.19% | +26.28% |
| May. 07 | Nordic Shares Closed Up Tuesday; Storskogen Group Series B Topped Leaders | DJ |
| May. 07 | Transcript : BioGaia AB, Q1 2024 Earnings Call, May 07, 2024 |
| Sales 2024 * | 1.42B 135M | Sales 2025 * | 1.58B 150M | Capitalization | 12.91B 1.23B |
|---|---|---|---|---|---|
| Net income 2024 * | 403M 38.36M | Net income 2025 * | 437M 41.6M | EV / Sales 2024 * | 8.19 x |
| Net cash position 2024 * | 1.25B 119M | Net cash position 2025 * | 962M 91.54M | EV / Sales 2025 * | 7.58 x |
| P/E ratio 2024 * |
32
x | P/E ratio 2025 * |
29.5
x | Employees | 211 |
| Yield 2024 * |
5.4% | Yield 2025 * |
5.4% | Free-Float | 80.06% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioGaia AB
More press releases
More news
| 1 day | +2.90% | ||
| 1 week | +1.19% | ||
| 1 month | +12.90% | ||
| 3 months | -1.84% | ||
| 6 months | +21.83% | ||
| Current year | +26.28% |
1 week
122.40
133.00
1 month
112.30136.60
Current year
101.00136.60
1 year
91.45136.60
3 years
68.88136.60
5 years
63.00136.60
10 years
30.20136.60
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 74 | 89-12-31 | |
Theresa Agnew
CEO | Chief Executive Officer | 58 | 23-08-31 |
| Director of Finance/CFO | 57 | 19-11-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 02-12-31 | |
| Founder | 74 | 89-12-31 | |
Barbro Fridén
BRD | Director/Board Member | 68 | 23-05-04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 746 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 127.8 | +2.90% | 2,006,735 |
| 24-05-30 | 124.2 | -0.96% | 64,676 |
| 24-05-29 | 125.4 | -1.18% | 80,537 |
| 24-05-28 | 126.9 | +0.08% | 72,428 |
| 24-05-27 | 126.8 | +0.40% | 64,946 |
Delayed Quote Nasdaq Stockholm, May 31, 2024 at 11:29 am EDT
More quotes
Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Companyâs activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licenseeâs dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The Company operates worldwide.
Sector
Pharmaceuticals
Calendar
2024-07-23
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
127.8
SEK
Average target price
140
SEK
Spread / Average Target
+9.55%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +26.28% | 1.23B | |
| -2.34% | 89.87B | |
| -3.95% | 37.57B | |
| +63.05% | 26.47B | |
| -22.14% | 14.25B | |
| -7.96% | 12.99B | |
| -9.33% | 11.93B | |
| -46.33% | 10.84B | |
| +5.77% | 9.11B | |
| -19.42% | 7.32B |
- Stock Market
- Equities
- BIOG B Stock
